- Home
- INTS vs AIMD Comparison
INTS vs AIMD Comparison
Compare INTS & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- AIMD
- Stock Information
- Founded
- INTS 2012
- AIMD 1984
- Country
- INTS United States
- AIMD United States
- Employees
- INTS N/A
- AIMD N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- INTS Health Care
- AIMD Health Care
- Exchange
- INTS Nasdaq
- AIMD Nasdaq
- Market Cap
- INTS 8.7M
- AIMD 8.2M
- IPO Year
- INTS 2023
- AIMD N/A
- Fundamental
- Price
- INTS $0.46
- AIMD $0.66
- Analyst Decision
- INTS Strong Buy
- AIMD
- Analyst Count
- INTS 3
- AIMD 0
- Target Price
- INTS $8.50
- AIMD N/A
- AVG Volume (30 Days)
- INTS 1.3M
- AIMD 393.2K
- Earning Date
- INTS 05-13-2025
- AIMD 08-04-2025
- Dividend Yield
- INTS N/A
- AIMD N/A
- EPS Growth
- INTS N/A
- AIMD N/A
- EPS
- INTS N/A
- AIMD N/A
- Revenue
- INTS N/A
- AIMD $106,207.00
- Revenue This Year
- INTS N/A
- AIMD N/A
- Revenue Next Year
- INTS N/A
- AIMD N/A
- P/E Ratio
- INTS N/A
- AIMD N/A
- Revenue Growth
- INTS N/A
- AIMD 13.38
- 52 Week Low
- INTS $0.29
- AIMD $0.40
- 52 Week High
- INTS $5.10
- AIMD $1.17
- Technical
- Relative Strength Index (RSI)
- INTS 38.44
- AIMD 60.11
- Support Level
- INTS $0.29
- AIMD $0.62
- Resistance Level
- INTS $0.63
- AIMD $0.80
- Average True Range (ATR)
- INTS 0.09
- AIMD 0.07
- MACD
- INTS 0.06
- AIMD 0.01
- Stochastic Oscillator
- INTS 50.88
- AIMD 60.64
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.